The World Health Organization said on Friday its partners such as Gavi and UNICEF can start buying mpox vaccines before they are approved by the U.N. health agency, to get inoculations to Africa faster as the continent battles an escalating outbreak of the virus.
Tag Archive for: Bavarian Nordic
The Danish company on Saturday announced plans to increase production of its vaccine Jynneos on the heels of the World Health Organization last week declaring mpox a global health emergency.
“Children and adolescents are disproportionally affected by mpox in the ongoing outbreak in Africa, highlighting the importance and urgency to broaden the access to vaccines and therapies for this vulnerable population,” Bavarian CEO Paul Chaplin said in a statement.
Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa’s top public health body, after the body declared an emergency.
A Phase II study funded by the National Institutes of Health found that a dose-sparing, intradermal regimen of Bavarian Nordic’s intradermal mpox vaccine Jynneos (modified vaccinia Ankara-Bavarian Nordic) can match the antibody response elicited by the standard-dose regimen.
According to Bavarian Nordic, its cancer vaccine TAEK-VAC has reached a stage where more investments are required. The company would also have faced stiff competition in the cancer vaccine space.
Yesterday the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend that individuals 18 years and older with certain risk factors should receive two doses of Jynneos.
The U.S. Food and Drug Administration has approved GSK Plc’s respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people.
Pfizer Inc and GSK are close to bringing the first two vaccines for RSV to the United States after gaining the backing of a panel of advisers to the FDA.
Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc. for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023.